Biblio

Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is N and Author is Nishimoto, Mitsutaka  [Clear All Filters]
2024
Moriguchi M, Ido K, Okamura H, Nakamae M, Sakatoku K, Makuuchi Y, Kuno M, Takakuwa T, Hirose A, Nishimoto M, et al. Impacts of Posttransplant Cyclophosphamide Dose on Graft-versus-leukemia Effects via HLA-B Leader in HLA-haploidentical Peripheral Blood Stem Cell Transplantation. Acta Haematol. 2024.
Okayama Y, Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Hirose A, Nakamae M, Nishimoto M, Nakashima Y, et al. Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission. Int J Hematol. 2024.
Tazoe K, Harada N, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Hirose A, Nakamae M, Nishimoto M, Nakashima Y, et al. Systemic inflammatory autoimmune disease before allogeneic hematopoietic stem cell transplantation is a risk factor for death in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Ann Hematol. 2024.
2023
Shiomi I, Makuuchi Y, Noura I, Kakuno S, Niki M, Kaimi Y, Ido K, Sakatoku K, Kuno M, Takakuwa T, et al. Invasive fungal infection caused by Blastobotrys mokoenaii in an immunocompromised patient with acute myeloid leukemia: A case report. J Infect Chemother. 2023.
Makuuchi Y, Nakashima Y, Nishimoto M, Koh H, Hino M, Nakamae H. Posttransplant cyclophosphamide contributes to the impairment of the graft-versus-leukemia effect and the amelioration of graft-versus-host disease with the suppression of alloreactive T cells in a murine stem cell transplant model. Exp Hematol. 2023.
Harada N, Okamura H, Makuuchi Y, Kuno M, Takakuwa T, Nakamae M, Nishimoto M, Nakashima Y, Koh H, Hino M, et al. Third HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide for relapsed acute leukemia. Bone Marrow Transplant. 2023.
2022
Nakamae H, Okamura H, Hirose A, Koh H, Nakashima Y, Nakamae M, Nishimoto M, Makuuchi Y, Kuno M, Harada N, et al. A Prospective Study of an HLA-Haploidentical Peripheral Blood Stem Cell Transplantation Regimen Based on Modification of the Dose of Posttransplant Cyclophosphamide for Poor Prognosis or Refractory Hematological Malignancies. Cell Transplant. 2022;31:9636897221112098.
Nakaya Y, Nakashima Y, Harada N, Yamada K, Makuuchi Y, Kuno M, Takakuwa T, Okamura H, Nanno S, Nishimoto M, et al. Successful treatment of proven coronavirus disease 2019-associated pulmonary aspergillosis with liposomal amphotericin B in a patient with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. J Infect Chemother. 2022.
Nishimoto M, Sogabe N, Hino M. Visceral disseminated varicella zoster virus infection following COVID-19 vaccination in an allogeneic stem cell transplant recipient. Transpl Infect Dis. 2022.
2019
Nishimoto M, Hirose A, Koh H, Nakamae M, Nanno S, Okamura H, Nakane T, Nakashima Y, Hino M, Nakamae H. Clinical impacts of using serum IL-6 level as an indicator of cytokine release syndrome after HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2019.
Takakuwa T, Okuno T, Nishimoto M, Nanno S, Takeoka Y, Nakashima Y, Koh H, Nakane T, Wanibuchi H, Hino M, et al. [Refractory ascites caused by lymphatic flow disorder after stem cell transplantation for acute myeloid leukemia]. Rinsho Ketsueki. 2019;60(1):12-16.